Abstract: Endometrial cancer is one of the common malignant tumors in gynecology, and its incidence is increasing year by year. Long non-coding RNA (lncRNA) is a member of the non-coding RNA family. In recent years, it has been found that it plays an important regulatory role in the pathological process of endometrial cancer and has become a research hotspot. LncRNA can be used as a promoter gene via human chromosome 10 deletion with phospho- and tensin homologue/phosphatidylinositol-3 kinase/protein kinase B/mammalian rapamycin target protein (PTEN/PI3K/AKT/mTOR), Wnt/β-catenin (Wnt/β-Catenin), extracellular signal-regulated kinase/adenylate-activated protein kinase (ERK/AMPK) and other signaling pathways to regulate proliferation, migration, invasion, and apoptosis of endometrial cancer cells. LncRNA can also inhibit the process of endometrial cancer through the PTEN/PI3K/AKT/mTOR pathway. In the process of lncRNA regulation of endometrial cancer, the formation of lncRNA-miRNA axis can be used as a new direction for future intervention therapy. LncRNA can also affect the drug resistance of chemotherapeutic drugs, and has important value for the diagnosis and prognosis of endometrial cancer. This review summarizes the recent studies of lncRNA and endometrial cancer, providing a theoretical basis for the diagnosis, prognosis or therapeutic targets of endometrial cancer.

Key words: Long-chain non-coding RNA, Endometrial neoplasms, Diagnosis, Prognosis